BTIG analyst Julian Harrison maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $61.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Julian Harrison’s rating is based on several promising developments in Viridian Therapeutics’ pipeline. The completion of enrollment for the Phase 3 trials of VRDN-003, with its subcutaneous delivery method, is a significant milestone. This method is expected to be preferred by payors over intravenous options due to its convenience and cost-effectiveness. The anticipated data readout in the first half of 2026 is seen as de-risked, given the shared binding domains with veligrotug, which has shown strong efficacy and safety profiles in previous trials.
Additionally, the potential for a Breakthrough Therapy Designation for veligrotug could expedite its commercial availability, enhancing Viridian’s market position. The company’s strengthened intellectual property portfolio, with patents extending into the 2040s, further supports its long-term prospects. These factors, combined with the positive early data from VRDN-006, contribute to a favorable outlook for Viridian Therapeutics, justifying the Buy rating.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.